...BRCA2 by age 40, and 86% for BRCA1 and 71% for BRCA2 by age 50. RRM usage was estimated to be 46% by age 70 in both BRCA...
...BRCA2 mutation or family history are recommended to undergo risk-reducing salpingo-oophorectomy (RRSO) after age 35 or c...
...BRCA2, as well as for vimentin. This cell line should be useful when testing new therapies for breast cancer in the Midd...
...BRCA2 gene, while mutations in other rare high and moderate-risk genes and common low penetrance variants may account fo...
...BRCA2, MSH6, PMS2, TP53, APC, CDH1), the results would have been positive only 6.2% of the time, instead of 17%. Results...
...BRCA2) with the development of breast and ovarian cancers have been widely researched and recognised. It is known that t...
...BRCA2 gene, associated with a high risk of breast and ovarian cancer, make their reproductive decisions. Using semi-stru...
...BRCA2 mutation had been identified in their family. Data collection consisted of an audio recorded, semi-structured inte...
...BRCA2 variants), 5 BRCA2 variants with no clinical importance and 22 polymorphisms (12 in BRCA1 and 10 in BRCA2) were al...
To estimate the frequency of BRCA1 and BRCA2 germline mutations in women with nonmucinous epithelial ovarian carcinoma u...
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
